COX-2 Inhibitor Research

COX-2 INHIBITOR RESEARCH......Page 5
NOTICE TO THE READER......Page 6
Contents......Page 7
Preface......Page 9
Abstract......Page 13
Introduction......Page 14
1. Prostaglandin Synthesis and COX......Page 16
2. COX and Gastritis and Gastric Ulcer......Page 18
3. COX-2 and Gastric Cancer......Page 19
4. COX-2 and H.Pylori Infected Gastric Cancer......Page 25
5. Mechanism Underlying COX-2 Caused Gastric Cancer......Page 28
1. Development and Pharmacology of COX-2 Inhibitor......Page 34
2. COX-2 Inhibitor and Gastric Cancer......Page 37
1. Introduction......Page 46
2. Mechanism Underlying COX-2 Dependent Pathway for Anticarcinogenesis......Page 47
3. Mechanism Underlying COX-2 Independent for Anti-Carcinogenes......Page 54
4. Mechanism Both (Combinated) of COX-2 Dependent and Independent Pathway......Page 58
Introduction......Page 59
1. Currently Unclear and/or Unsolved Issues for COX-2 Inhibitor asClinical Agent......Page 65
2. Currently Status and Future Prospect Of COX-2 Inhibitor for Anti-Tumor......Page 70
References......Page 76
Abstract......Page 97
Diet and Gastric Cancer: Observational Epidemiology Studies......Page 99
Interventional Dietary Trials for Prevention of Gastric Cancer......Page 104
c) Food Components that Intercept DNA Reactive Species......Page 107
Helicobacter Pylori and Gastric Cancer......Page 108
COX-2 Inhibitors and Gastric Cancer: Experimental in Vitro Studies......Page 110
COX-2 and Gastric Cancer: Animal Models or Experimental In Vivo Studies......Page 111
Conclusions......Page 115
References......Page 116
Introduction......Page 127
Functions of Cyclooxygenases......Page 128
Cyclooxygenase Genes......Page 130
Genetic Models......Page 131
Prostanoids Receptors......Page 133
Molecular Mechanisms by which COX-2 Contributes to Cancer......Page 134
COX-2 and Apoptosis......Page 135
COX-2 and Angiogenesis......Page 136
Multidrug Resistance......Page 137
Cox-2-Independent Effects......Page 138
COX-2 and Endocannabinoids......Page 139
Acknowledgements......Page 140
References......Page 141
Abstract......Page 157
Introduction......Page 158
Prostaglandin Synthesis......Page 159
Cyclooxygenase Function......Page 160
Prostaglandins in Renal Physiology......Page 161
Prostaglandins in Pathophysiologic States......Page 163
Hemodynamic ARF......Page 164
Edema......Page 166
Hyperkalemia......Page 167
Acute Interstitial Nephritis......Page 168
Animal Studies......Page 169
Human Studies......Page 171
Renal Blood Flow/Glomerular Filtration Rate......Page 172
Sodium Balance......Page 176
Water and Potassium Balance......Page 183
AIN from Selective COX-2 Inhibitors......Page 184
References......Page 185
Abstract......Page 193
1. Introduction......Page 194
Arachidonic Acid Metabolism......Page 195
Chemical Structures of COX-2 Inhibitors......Page 197
COX-2 Inhibitors and Chemopreventive Actions......Page 198
2.2. Cell Culture......Page 200
2.4. Measurement of ROS Production in Cellular Systems......Page 201
2.6. Measuring of the Equine MPO by ELISA......Page 202
2.7. Cell-Free Systems......Page 203
3.1. Cellular Systems......Page 204
3.2. Cell-Free Systems......Page 209
4. Discussion......Page 211
References......Page 214
Abstract......Page 221
Introduction......Page 222
Cycloxygenase......Page 223
Controversy Concerning Selective COX-2 Inhibitors......Page 225
Lipoxygenases......Page 226
Dual COX/5-LOX Inhibitors......Page 229
Defining the Binding Cavity of Human 5-Lipoxygenase Model......Page 231
Molecular Modelling of Ligands......Page 233
Molecular Dynamics Simulations......Page 234
Docking in Human COX-2 and 5-LOX Models......Page 235
COX-2 Binding Mode......Page 238
5-LOX Binding Mode......Page 240
Selective Cyclooxygenase Inhibitors......Page 242
Dual COX/5-LOX Inhibitors......Page 243
References......Page 244
Index......Page 249